

Human Coagulation Factor VII Alexa Fluor® 647-conjugated Antibody

Monoclonal Mouse IgG_{2B} Clone # 321605

Catalog Number: FAB23381R

00 µg

DESCRIPTION			
Species Reactivity	Human		
Specificity	Detects human Coagulation Factor VII in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) Kallikrein-1, -2, -4, -5, -7, -8, -9, -10, -11, -12, -13, -14, -15, -B1, rhHGFA, rhFactor X, rhFactor XI, rhThrombin, rhuPA, or rhPROC is observed.		
Source	Monoclonal Mouse IgG _{2B} Clone # 321605		
Purification	Protein A or G purified from hybridoma culture supernatant		
Immunogen	Mouse myeloma cell line NS0-derived recombinant human Coagulation Factor VII Ala39-Pro444 Accession # NP_062562		
Conjugate	Alexa Fluor 647 Excitation Wavelength: 650 nm Emission Wavelength: 668 nm		
Formulation	Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.		
	*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.		

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.			
	Recommended Concentration	Sample	
Flow Cytometry	0.25-1 μg/10 ⁶ cells	HASMC human aortic smooth muscle cells	
PREPARATION AND S	STORAGE		
Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.		
Stability & Storage	Protect from light. Do not freeze.		

BACKGROUND

APPLICATIONS

Coagulation Factors VII and VIIa refer to the pro and active forms of the same protease, respectively (1). Factor VII is synthesized in the liver and circulates in the plasma where it binds to tissue factor (TF), an integral membrane protein found in a variety of cell types. Upon binding of TF, Factor VII is rapidly converted into VIIa. The resulting 1:1 complex of VIIa and TF initiates the coagulation pathway and has also important coagulation-independent functions such as angiognesis (2). The cleavage and activation of Coagulation Factors VII, IX and X by VIIa:TF is phospholipid-dependent whereas the cleavage of small peptide substrates is not (1). The predominant splicing variant of Factor VII in normal liver corresponds to the 444 amino acid precursor (3, 4). After a signal peptide (residues 1-38), the mature chain can be further processed into the light chain (residues 39-190) and the heavy chain (residues 191-444). The purified rhFactor VII corresponds to the mature chain, which can be processed and activated by treatment with thermolysin and binding with rhTissue Factor (R&D Systems, Catalog # 2339-PA) under the conditions described above.

References:

1. Morrissey, J.H. (2004) in *Handbook of Proteolytic Enzymes*, Barrett, A.J. et al. eds. p. 1659.

• 12 months from date of receipt, 2 to 8 °C as supplied.

- 2. Versteeg, H.H. et al. (2003) Carcinogenesis 24:1009.
- 3. Hagen, F.S. et al. (1986) Proc. Natl. Acad. Sci. USA 83:2412.
- 4. O'Hara, P.J. et al. (1987) Proc. Natl. Acad. Sci. USA 84:5158.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 2/6/2018 Page 1 of 1

